Table 5 Role of CAR.MSCs
From: The role of MSCs and CAR-MSCs in cellular immunotherapy
MSCs origin | CAR type | Cytokine secretion of T cells | T cell proliferation | MSCs proliferation | Tumor cell | Killing ability | Ref |
|---|---|---|---|---|---|---|---|
Human adipose tissue | Anti-GD2 CAR lacks the intracellular signaling domain with mTRAIL | / | / | / | GBM cell lines (T98G, U87MG, and A172), primary C3c GBM cells | Robust cytotoxic effect | [132] |
Human adipose tissue | Anti-GD2 CAR lacks the intracellular signaling domain with TRAIL | / | / | Prolonged persistence | ES cell lines(TC71, A673) | Significant antitumour activities | [133] |
Human SCP-1 cell line | Anti-CD33-anti-CD3 bsAb with 4-1BBL | Increase the section of TNF-α and IFN-γ | Upregulated the activation markers CD69 and CD25, Pronounced proliferation | / | Human AML cell lines U937 and MOLM-13, OCI-AML3 | Improvement of T-cell-mediated tumor cell killing | [134] |